Drug Trial Radar · NCT04984434
Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jul 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
68
Planned (sponsor's estimate)
Start
Jul 30, 2021
Primary completion
Jul 30, 2023
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- Shandong New Time Pharmaceutical Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Jul 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Multiple center, Open-label, dose escalation Phase Ⅰ clinical study. The purpose is to evaluate the safety and tolerability of F182112 when infused intravenously (IV) and determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of F182112 when infused IV.
Conditions
- Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
Interventions
F182112Drug
Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTsTime frame: Up to 28 days
- Maximum Tolerated Dose (MTD)Time frame: Approximately 12 months
- RP2DTime frame: Approximately 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shaohong Yin
Linyi, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.